IONS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

86.670

Open

84.420

VWAP

85.32

Vol

2.65M

Mkt Cap

14.27B

Low

82.950

Amount

225.81M

EV/EBITDA(TTM)

Total Shares

165.26M

14.17B

EV/OCF(TTM)

P/S(TTM)

13.15

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Events Timeline

(ET)

2026-06-25

05:30:00

Ionis Enters License Agreement with Recordati for Zilganersen

2026-06-24 (ET)

2026-06-24

15:00:00

Ionis Receives FDA Approval for TRYNGOLZA to Reduce Triglycerides

2026-06-24

12:00:00

FDA Approves Ionis Pharmaceuticals' Tryngolza for Reducing Triglycerides

2026-05-28 (ET)

2026-05-28

05:20:00

GSK Announces Bepirovirsen Trial Data, 19% Functional Cure Rate Achieved

News

5.0

06-30Yahoo Finance

Executive Departure: Eugene Schneider Leaves Role

8.5

06-26NASDAQ.COM

Biotech Sector Update: FDA and EU Approvals

9.0

06-25Newsfilter

Ionis Secures FDA Approval for Tryngolza and Signs Recordati Licensing Deal for Zilganersen

8.5

06-25NASDAQ.COM

Ionis Enters License Agreement with Recordati for Zilganersen

9.0

06-25NASDAQ.COM

Ionis Pharmaceuticals Receives FDA Approval for TRYNGOLZA

7.5

06-25seekingalpha

Ionis Pharmaceuticals Enters License Agreement with Recordati for Zilganersen

14 Analyst Rating

Wall Street analysts forecast IONS stock price to rise

13 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

65.00

Averages

92.67

High

110.00

Current: 0.000

Low

65.00

Averages

92.67

High

110.00

H.C. Wainwright

Buy

maintain

$125 -> $130

AI Analysis

2026-06-25

Reason

H.C. Wainwright

Price Target

$125 -> $130

AI Analysis

2026-06-25

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Ionis Pharmaceuticals to $130 from $125 and keeps a Buy rating on the shares following the FDA approval of Tryngolza.

Goldman Sachs

Neutral

maintain

$74 -> $75

2026-06-24

Reason

Goldman Sachs

Price Target

$74 -> $75

2026-06-24

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Ionis Pharmaceuticals to $75 from $74 and keeps a Neutral rating on the shares. The firm cites the FDA having approved Tryngolza, used with diet, to reduce triglyceridesand the risk of acute pancreatitis in adults with severe hypertriglyceridemia, or SHTG, based on the Phase 3 trials where TGs were lowered by up to 72% and AP by up to 91%. The inclusion of AP risk reduction is a positive, and the firm notes the new guidance to consider liver enzyme testing at baseline and on dosage increase in the context of liver fat and enzyme elevations in the Warnings and Precautions section, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IONS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Ionis Pharmaceuticals Inc (IONS.O) is 96.15, compared to its 5-year average forward P/E of -7.00. For a more detailed relative valuation and DCF analysis to assess Ionis Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.00

Current PE

96.15

Overvalued PE

28.08

Undervalued PE

-42.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.39

Current EV/EBITDA

-22.74

Overvalued EV/EBITDA

-7.14

Undervalued EV/EBITDA

-19.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.52

Current PS

9.13

Overvalued PS

11.72

Undervalued PS

7.32

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

give me stocks bullish for next week

Intellectia · 575 candidates

Price: >= $-100.00Rsi Category: moderateMoving Average Relationship: PriceAboveMA5, PriceAboveMA20Ema 5: >= -100Ema 20: >= -100One Week Rise Prob: >= 50One Week Predict Return: >= 0.0%Macd: bullish, positive

Ticker

Name

Market Cap$

WDC

Western Digital Corp

221.92B

JBTM

JBT Marel Corp

7.00B

INTS

Intensity Therapeutics Inc

11.03M

WFCF

Where Food Comes From Inc

61.46M

VISN

Vistance Networks Inc

2.83B

SMHI

SEACOR Marine Holdings Inc

212.71M

stock choice U.S. to make money

Intellectia · 69 candidates

Market Cap: >= 2.00BPrice: >= $-100.00Volume: >= 1,000,000Quarter Revenue Yoy Growth: >= 10.0%Analyst Consensus: Strong Buy, Moderate BuyRsi Category: moderatePe Ttm: <= 35Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00Ema 20: >= -100Ema 200: >= -100Ev Ebitda: <= 25

Ticker

Name

Market Cap$

QUBT

Quantum Computing Inc

2.63B

CYTK

Cytokinetics Inc

10.36B

IONQ

IONQ Inc

23.75B

EBC

Eastern Bankshares Inc

4.67B

EOSE

Eos Energy Enterprises Inc

2.96B

RGTI

Rigetti Computing Inc

8.33B

stock of the week - for swing trade ?

Intellectia · 496 candidates

Market Cap: >= 2.00BRegion: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 60Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Axos Financial Inc

5.69B

IONS

Ionis Pharmaceuticals Inc

14.01B

HXL

Hexcel Corp

6.48B

ITT

ITT Inc

17.48B

IPAR

Interparfums Inc

3.28B

Coca-Cola Co

334.69B

what are the best buys for short term

Intellectia · 67 candidates

Market Cap: >= 5.00BMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $3.00 - $15.00One Week Rise Prob: >= 70Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

PBR

Petroleo Brasileiro SA Petrobras

92.03B

ELF

elf Beauty Inc

5.62B

AXSM

Axsome Therapeutics Inc

9.37B

DXCM

Dexcom Inc

28.42B

ARM

Arm Holdings PLC

123.15B

MKSI

MKS Inc

14.58B

give me some good optioms for tomorrow

Intellectia · 24 candidates

Market Cap: >= 5.00BRelative Vol: >= 1.50Weekly Average Turnover: >= 20,000,000Rsi 14: 45 - 55Week Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Morgan Stanley

290.20B

GEV

GE Vernova Inc

181.21B

ARM

Arm Holdings PLC

120.87B

ENB

Enbridge Inc

103.23B

PBR.A

Petroleo Brasileiro SA Petrobras

81.46B

TFC

Truist Financial Corp

63.15B

good day trading stock for today

Intellectia · 46 candidates

Price Change Pct: >= $0.00Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Rsi 14: 45 - 55Moving Average Relationship: PriceCrossAboveMA5

Ticker

Name

Market Cap$

ARM

Arm Holdings PLC

120.87B

TFC

Truist Financial Corp

63.15B

SPG

Simon Property Group Inc

60.42B

EOG

EOG Resources Inc

58.63B

Edwards Lifesciences Corp

49.41B

PEG

Public Service Enterprise Group Inc

39.82B

en health care quien está hoy a la alza

Intellectia · 64 candidates

Price Change Pct: >= $0.00Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA5

Ticker

Name

Market Cap$

TMO

Thermo Fisher Scientific Inc

239.06B

AMGN

Amgen Inc

185.02B

DHR

Danaher Corp

170.97B

MDT

Medtronic PLC

128.57B

VRTX

Vertex Pharmaceuticals Inc

117.00B

Edwards Lifesciences Corp

49.41B

Whales Holding IONS

Summit Partners Public Asset Management, LLC

Eventide Asset Management, LLC

Bellevue Asset Management AG

Deerfield Management Company, L.P.

Pinnacle Associates, Ltd.

Eversept Partners, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Ionis Pharmaceuticals Inc (IONS) stock price today?

The current price of IONS is 86.33 USD — it has increased 3.79

What is Ionis Pharmaceuticals Inc (IONS)'s business?

What is the price predicton of IONS Stock?

Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is92.67 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.